ABSTRACT
El esófago de Barrett (EB) se define como la condición en la cual una mucosa columnar metaplásica predispuesta a neoplasia reemplaza la mucosa escamosa del esófago distal. La guías actuales recomiendan que el diagnóstico requiere el hallazgo de metaplasia intestinal (MI) con células caliciformes de al menos 1 cm de longitud. El EB afecta aproximadamente al 1% de la población general y hasta en 14% de los pacientes con enfermedad por reflujo gastroesofágico (ERGE). El EB es precursor del adenocarcinoma esofágico (ACE), neoplasia en aumento en países occidentales. Los principales factores de riesgo descritos para ACE asociado a EB son: sexo masculino, edad > 50 años, obesidad central y tabaquismo. El riesgo anual de ACE en EB sin displasia, displasia de bajo (DBG) y alto grado es 0,1-0,3%, 0,5% y 5-8%, respectivamente. El tratamiento del EB no displásico consiste en un cambio de estilo de vida saludable, quimioprevención mediante inhibidores de la bomba de protones y vigilancia endoscópica cada 3 a 5 años. Se recomienda que a partir de la presencia de DBG los pacientes sean referidos a un centro experto para la confirmación del diagnóstico, estadio y así definir su manejo. En pacientes con EB y displasia o cáncer incipiente, el tratamiento endoscópico consiste en la resección y ablación, con un éxito cercano al 90%. El principal evento adverso es la estenosis esofágica que es manejada endoscópicamente.
Barrett's esophagus (BE) is the condition in which a metaplastic columnar mucosa predisposed to neoplasia replaces the squamous mucosa of the distal esophagus. The current guidelines recommends that diagnosis requires the finding of intestinal metaplasia (IM) with goblet cells of at least 1 cm in length. BE affects approximately 1% of the general population and up to 14% of patients with gastroesophageal reflux disease (GERD). BE is a precursor of esophageal adenocarcinoma (EAC), which has increased in western countries. The main risk factors described for EAC associated with BE are male sex, age > 50 years, central obesity and tobacco use. Annual risk of EAC in patients with BE without dysplasia, low grade (LGD) and high-grade dysplasia is 0,1-0,3%, 0,5% y 5-8%, respectively. Treatment of non-dysplastic BE consists mainly of a healthy lifestyle change, chemoprevention with proton pump inhibitors and surveillance endoscopy every 3 to 5 years. It is recommended that from the presence of LGD patients are referred to an expert center for confirmation of the diagnosis, stage and thus define their management. In patients with BE and dysplasia or early-stage cancer, endoscopic therapy with resection and ablation is successful in about 90% of the patients. The main adverse event is esophageal stricture, which is managed endoscopically.
Subject(s)
Humans , Male , Barrett Esophagus/diagnosis , Barrett Esophagus/etiology , Barrett Esophagus/therapy , Esophageal Neoplasms/diagnosis , Esophageal Neoplasms/etiology , Esophageal Neoplasms/therapy , Adenocarcinoma/diagnosis , Adenocarcinoma/etiology , Adenocarcinoma/pathology , Precancerous Conditions/diagnosis , Precancerous Conditions/therapy , Risk Factors , EsophagoscopyABSTRACT
Barrett's esophagus (BE) is the condition in which a metaplastic columnar mucosa predisposed to neoplasia replaces the squamous mucosa of the distal esophagus. The current guidelines recommends that diagnosis requires the finding of intestinal metaplasia (IM) with goblet cells of at least 1 cm in length. BE affects approximately 1% of the general population and up to 14% of patients with gastroesophageal reflux disease (GERD). BE is a precursor of esophageal adenocarcinoma (EAC), which has increased in western countries. The main risk factors described for EAC associated with BE are male sex, age > 50 years, central obesity and tobacco use. Annual risk of EAC in patients with BE without dysplasia, low grade (LGD) and high-grade dysplasia is 0,1-0,3%, 0,5% y 5-8%, respectively. Treatment of non-dysplastic BE consists mainly of a healthy lifestyle change, chemoprevention with proton pump inhibitors and surveillance endoscopy every 3 to 5 years. It is recommended that from the presence of LGD patients are referred to an expert center for confirmation of the diagnosis, stage and thus define their management. In patients with BE and dysplasia or early-stage cancer, endoscopic therapy with resection and ablation is successful in about 90% of the patients. The main adverse event is esophageal stricture, which is managed endoscopically.
Subject(s)
Adenocarcinoma , Barrett Esophagus , Esophageal Neoplasms , Humans , Barrett Esophagus/therapy , Barrett Esophagus/diagnosis , Barrett Esophagus/etiology , Esophageal Neoplasms/etiology , Esophageal Neoplasms/diagnosis , Esophageal Neoplasms/therapy , Risk Factors , Adenocarcinoma/etiology , Adenocarcinoma/diagnosis , Adenocarcinoma/pathology , Precancerous Conditions/therapy , Precancerous Conditions/diagnosis , Male , EsophagoscopyABSTRACT
Pancreatic cystic neoplasms (PCN) are frequently detected on abdominal images performed for non-pancreatic indications. Their prevalence in asymptomatic population ranges from 2.7 to 24.8%, and increases with age. There are several types of pancreatic cysts. Some may contain cancer or have malignant potential, such as mucinous cystic neoplasms, including mucinous cystadenoma (MCN) and intraductal papillary mucinous neoplasms (IPMN). In contrast, others are benign, such as serous cystadenoma (SCA). However, even those cysts with malignant potential rarely progress to cancer. Currently, the only treatment for pancreatic cysts is surgery, which is associated with high morbidity and occasional mortality. The Board of the Chilean Pancreas Club of the Chilean Gastroenterology Society developed the first Chilean multidisciplinary consensus for diagnosis, management, and surveillance of PCN. Thirty experts were invited and answered 21 statements with five possible alternatives: 1) fully agree; 2) partially agree; 3) undecided; 4) disagree and 5) strongly disagree. A consensus was adopted when at least 80% of the sum of the answers "fully agree" and "partially agree" was reached. The consensus was approved by the Board of Directors of the Chilean Pancreas Club for publication.
Subject(s)
Humans , Pancreatic Cyst/diagnosis , Pancreatic Cyst/therapy , Pancreatic Neoplasms/diagnosis , Pancreatic Neoplasms/pathology , Pancreatic Neoplasms/therapy , Chile/epidemiology , ConsensusABSTRACT
Pancreatic cystic neoplasms (PCN) are frequently detected on abdominal images performed for non-pancreatic indications. Their prevalence in asymptomatic population ranges from 2.7 to 24.8%, and increases with age. There are several types of pancreatic cysts. Some may contain cancer or have malignant potential, such as mucinous cystic neoplasms, including mucinous cystadenoma (MCN) and intraductal papillary mucinous neoplasms (IPMN). In contrast, others are benign, such as serous cystadenoma (SCA). However, even those cysts with malignant potential rarely progress to cancer. Currently, the only treatment for pancreatic cysts is surgery, which is associated with high morbidity and occasional mortality. The Board of the Chilean Pancreas Club of the Chilean Gastroenterology Society developed the first Chilean multidisciplinary consensus for diagnosis, management, and surveillance of PCN. Thirty experts were invited and answered 21 statements with five possible alternatives: 1) fully agree; 2) partially agree; 3) undecided; 4) disagree and 5) strongly disagree. A consensus was adopted when at least 80% of the sum of the answers "fully agree" and "partially agree" was reached. The consensus was approved by the Board of Directors of the Chilean Pancreas Club for publication.
Subject(s)
Pancreatic Cyst , Pancreatic Neoplasms , Humans , Chile/epidemiology , Consensus , Pancreatic Cyst/diagnosis , Pancreatic Cyst/therapy , Pancreatic Neoplasms/diagnosis , Pancreatic Neoplasms/pathology , Pancreatic Neoplasms/therapyABSTRACT
Natural orifice transluminal endoscopic surgery (notes), is a novel approach to the peritoneal cavity, that has been used for both diagnostic and surgical procedures. Aims: to evaluated the safety and feasibility of per-oral transgastric route for peritoneal approach and for several basic surgical techniques in a porcine experimental model. Material and methods: five pigs entered in the study. Under general anesthesia , a conventional endoscope was passed into the stomach, the gastric wall was punctured by mean of a sphincterotome and the size of the gastric incision was increased with a cholecystectomy and intestinal loops mobilization were attempted. Gastric incision closure was performed with endoloops. Results: a good observation of the peritoneal cavity was achieved. Liver samples were obtained in all procedures as well as mobilization of small intestinal loops. Cholecystectomy was possible in only three cases. Conclusion: transgastric approach to the peritoneal cavity seems to be a potential alternative to the classical laparotomy and laparoscopic technique.
La cirugía endoscópica transluminal por orificios naturales (NOTES) es un nuevo abordaje a la cavidad peritoneal que ha sido utilizada ya sea como procedimiento diagnóstico o quirúrgico. Objetivos: Evaluar la seguridad y factibilidad de la ruta per-oral transgástrica para el acceso a la cavidad peritoneal , y para la realización de técnicas quirúrgicas básicas en un modelo experimental porcino. Material y métodos: Se utilizaron cinco cerdos. Bajo anestesia general mediante un endoscopio convencional se accedió al estómago y se puncionó la pared gástrica mediante un papilótomo. La abertura se amplió ya sea con papilótomo o con balón. Se exploró la cavidad peritoneal y se intentó realizar: biopsias hepáticas en todos los procedimientos, lo mismo ocurrió con la movilización de asas intestinales. La colecistectomía fue posible en sólo tres ocasiones. Conclusión: el abordaje transgástrico de la cavidad peritoneal pareciera ser una potencial alternativa a la laparotomía clásica y laparoscópica.